Identification

Name
Benzocaine
Accession Number
DB01086  (APRD00539)
Type
Small Molecule
Groups
Approved, Investigational
Description

A surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. [PubChem]

Structure
Thumb
Synonyms
  • 4-aminobenzoic acid ethyl ester
  • Amben ethyl ester
  • Benzocaina
  • Benzocaine
  • Benzocainum
  • Ethyl Aminobenzoate
  • Ethyl p-Aminobenzoate
  • Ethyl p-Aminophenylcarboxylate
  • p-(Ethoxycarbonyl)aniline
  • p-Carbethoxyaniline
  • p-Ethoxycarboxylic Aniline
External IDs
AR-01 / AR01 / NSC-41531 / NSC-4688
Product Ingredients
IngredientUNIICASInChI Key
Benzocaine hydrochlorideOG625Z9LEO23239-88-5JAADDQHUJDUAKW-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Anal Swabs 20%Stick20 %TopicalEndovations Inc.1988-12-311997-07-15Canada
Endocaine Spray 20%Spray20 %Buccal; OralEndovations Inc.1988-12-311997-07-15Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
20/20 Topical AnestheticStrip10 mg/1DentalAdvanced Dental Anesthetics2012-02-28Not applicableUs
7 Select Oral Pain Maximum Strength ReliefGel200 mg/gTopical7 Eleven2016-12-08Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Advance Topical Anesthetic GelGel200 mg/gDentalThe Atlanta Dental Supply Company Dba Advanced Dental Products2017-03-01Not applicableUs
Adventure Medical Kits Dental MedicKitOral; TopicalTender Corporation2012-09-19Not applicableUs
Aftertest Pain ReliefStick100 mg/mLTopicalDiabetic Supply Of Suncoast, Inc.2017-01-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSIBenzocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Ethanol + Ibuprofen + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSIBenzocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Ethanol + Ibuprofen + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
3M Nexcare Cold Sore TreatmentBenzocaine (50 mg/g) + Allantoin (10 mg/g)OintmentTopical3 M Pharmaceuticals2008-02-20Not applicableUs
50 Person ANSIBenzocaine + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Ethanol + Ibuprofen + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
ACME FIRST AID Contains 404 PIECESBenzocaine + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Ethanol + Isopropyl Alcohol + Lidocaine + Neomycin sulfate + Polymyxin B Sulfate + WaterKitAcme United Corporation2010-04-27Not applicableUs
ActisepBenzocaine (2 g/100mL) + Cetylpyridinium (.1 g/100mL) + Menthol (.5 g/100mL)SolutionTopicalActipharma, Inc2015-12-28Not applicableUs
ActisepBenzocaine (2 g/100mL) + Cetylpyridinium chloride (.1 g/100mL) + Menthol (.5 g/100mL)SprayTopicalActipharma, Inc2015-12-28Not applicableUs
Adventure First Aid .5 TinBenzocaine + Benzalkonium chloride + EthanolKitOral; TopicalTender Corporation2015-10-01Not applicableUs
Adventure First Aid Water ResistantBenzocaine + EthanolKitOral; TopicalTender Corporation2015-10-01Not applicableUs
Adventure Medical Kits 1 Person First AidBenzocaine (6 mL/100mL) + Benzalkonium chloride (0.4 mL/100mL) + Ethanol (60 mL/100mL)KitTender Corp Dba Adventure Medical Kits2010-08-25Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acella Antipyrine and Benzocaine OticBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Proficient Rx LP2010-11-092016-01-05Us
Acella Antipyrine and Benzocaine OticBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Acella Pharmaceuticals, LLC2010-11-092016-12-01Us
AdazinBenzocaine (2 g/100g) + Capsaicin (.035 g/100g) + Lidocaine (2 g/100g) + Methyl salicylate (1 g/100g)CreamTopicalSterling Knight Pharmaceuticals, Llc2014-12-03Not applicableUs
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Bauch & Lomb Incorporated1990-09-302017-05-31Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)LiquidTopicalDirectrx2014-01-012016-04-05Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Lake Erie Medical Dba Quality Care Produts Llc2009-04-302016-01-12Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Boca Pharmacal, Inc.2009-04-302016-01-31Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Directrx2014-01-012017-07-27Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Aidarex Pharmaceuticals LLC1990-09-302016-04-05Us
Antipyrine and BenzocaineBenzocaine (14 mg/mL) + Antipyrine (54 mg/mL)SolutionAuricular (otic)Proficient Rx LP2000-01-012016-01-05Us
International/Other Brands
Anacaine / Anaesthesin / Anbesol Baby / Dermoplast
Categories
UNII
U3RSY48JW5
CAS number
94-09-7
Weight
Average: 165.1891
Monoisotopic: 165.078978601
Chemical Formula
C9H11NO2
InChI Key
BLFLLBZGZJTVJG-UHFFFAOYSA-N
InChI
InChI=1S/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3
IUPAC Name
ethyl 4-aminobenzoate
SMILES
CCOC(=O)C1=CC=C(N)C=C1

Pharmacology

Indication

For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea, urinary tract, vagina. It is also used to suppress gag reflex.

Associated Conditions
Pharmacodynamics

Benzocaine is a local anesthetic commonly used as a topical pain reliever. It is the active ingredient in many over-the-counter analgesic ointments. It is also indicated for general use as a lubricant and topical anesthetic on intratracheal catheters and pharyngeal and nasal airways to obtund the pharyngeal and tracheal reflexes; on nasogastric and endoscopic tubes; urinary catheters; laryngoscopes; proctoscopes; sigmoidoscopes and vaginal specula.

Mechanism of action

Benzocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

LD50=3040 mg/kg (rat, oral)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Benzocaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Benzocaine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Benzocaine is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Benzocaine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Benzocaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Benzocaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Benzocaine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Benzocaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Benzocaine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzocaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Benzocaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Azaperone.Investigational, Vet Approved
AzelastineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Benzocaine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Benperidol.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzocaine is combined with Benzyl alcohol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Benzocaine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Benzocaine.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Benzocaine.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Benzocaine.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Benzocaine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Benzocaine.Approved, Investigational
BuprenorphineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Benzocaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Benzocaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Benzocaine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Benzocaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Benzocaine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benzocaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Benzocaine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Benzocaine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Benzocaine.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Benzocaine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Benzocaine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Benzocaine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Benzocaine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Benzocaine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Benzocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Benzocaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Benzocaine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Benzocaine.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Benzocaine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Benzocaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Benzocaine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Benzocaine.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Benzocaine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Benzocaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Benzocaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Benzocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Benzocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Benzocaine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Benzocaine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Benzocaine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Benzocaine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Benzocaine.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Benzocaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Benzocaine.Approved, Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Benzocaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Benzocaine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Benzocaine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Benzocaine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Benzocaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Benzocaine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Benzocaine.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Benzocaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Benzocaine.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Benzocaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Benzocaine.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Benzocaine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Benzocaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Benzocaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Benzocaine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Benzocaine.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Benzocaine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Benzocaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Benzocaine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Benzocaine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Benzocaine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Benzocaine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Benzocaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Benzocaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Benzocaine.Approved, Investigational
EthanolBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Benzocaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Benzocaine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Benzocaine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzocaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Benzocaine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Benzocaine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Benzocaine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Benzocaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Benzocaine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Benzocaine.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Benzocaine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Benzocaine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzocaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Benzocaine.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Benzocaine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Benzocaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Benzocaine.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Benzocaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Benzocaine.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Benzocaine.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Benzocaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Benzocaine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Benzocaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Benzocaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Benzocaine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzocaine.Approved, Investigational
HydrocodoneBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Benzocaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Benzocaine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Benzocaine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Benzocaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Benzocaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzocaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Benzocaine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Benzocaine.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Benzocaine.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Benzocaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Benzocaine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Benzocaine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Benzocaine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Benzocaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Benzocaine.Approved, Vet Approved
Lithium cationThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lithium.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Benzocaine can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Benzocaine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Benzocaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzocaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Benzocaine.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Benzocaine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benzocaine.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Benzocaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Benzocaine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Benzocaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzocaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Benzocaine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Benzocaine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Benzocaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Benzocaine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzocaine.Approved
MethotrimeprazineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Benzocaine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzocaine.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Benzocaine.Approved
MetyrosineBenzocaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Benzocaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Benzocaine is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Investigational
MirtazapineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Benzocaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Benzocaine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Benzocaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Benzocaine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Benzocaine.Approved
Nitrous acidThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Benzocaine.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Benzocaine.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Benzocaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benzocaine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Benzocaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Benzocaine is combined with Opium.Approved, Illicit
OrphenadrineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Benzocaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzocaine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Benzocaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Benzocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Benzocaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Benzocaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Benzocaine.Approved
ParaldehydeBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Benzocaine.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Benzocaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Benzocaine.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Benzocaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Benzocaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Benzocaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Benzocaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Benzocaine.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Benzocaine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Benzocaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Benzocaine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Benzocaine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benzocaine.Approved
PramipexoleBenzocaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Benzocaine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Benzocaine.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Benzocaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzocaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Benzocaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Benzocaine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Benzocaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Benzocaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Benzocaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Benzocaine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Benzocaine.Approved
PSD502The risk or severity of adverse effects can be increased when Benzocaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Benzocaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Benzocaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Benzocaine.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Benzocaine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzocaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Benzocaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Benzocaine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Benzocaine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzocaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Romifidine.Vet Approved
RopiniroleBenzocaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Benzocaine.Approved
RotigotineBenzocaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Benzocaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Benzocaine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzocaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benzocaine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Benzocaine.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Benzocaine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Benzocaine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sultopride.Experimental
SuvorexantBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Benzocaine.Approved, Investigational
Technetium Tc-99m tilmanoceptBenzocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Benzocaine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Benzocaine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tetrodotoxin.Investigational
ThalidomideBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Benzocaine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Benzocaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Benzocaine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Benzocaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Benzocaine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Benzocaine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Benzocaine.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Benzocaine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Benzocaine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Benzocaine.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Benzocaine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Benzocaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Benzocaine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Benzocaine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Benzocaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Benzocaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Benzocaine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Benzocaine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Benzocaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Benzocaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Benzocaine.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Benzocaine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Benzocaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Benzocaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Benzocaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Benzocaine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Benzocaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zolazepam.Vet Approved
ZolpidemBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Benzocaine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Benzocaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Benzocaine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0004992
KEGG Drug
D00552
KEGG Compound
C07527
PubChem Compound
2337
PubChem Substance
46508891
ChemSpider
13854242
ChEBI
116735
ChEMBL
CHEMBL278172
Therapeutic Targets Database
DAP001234
PharmGKB
PA448576
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Benzocaine
ATC Codes
R02AD01 — BenzocaineD04AB04 — BenzocaineN01BA05 — BenzocaineC05AD03 — Benzocaine
AHFS Codes
  • 84:08.00 — Antipruritics and Local Anesthetics
  • 52:16.00 — Local Anesthetics
MSDS
Download (73.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Enrolling by InvitationBasic ScienceBMI >30 kg/m21
1, 2TerminatedTreatmentMaternal Nipple Pain Upon Breastfeeding / Neonatal Latch Difficulties / Neonatal Tongue-tie1
2CompletedPreventionAnaesthesia therapy1
2CompletedPreventionNo Disease State or Condition1
2CompletedSupportive CareOtitis Media (OM) / Pain1
2CompletedTreatmentAcute Otitis Media1
2CompletedTreatmentAcute Otitis Media / Pain1
2Enrolling by InvitationPreventionNormal Pulp/ Pulpitis1
3CompletedTreatmentAcute Otitis Media1
3CompletedTreatmentAcute Otitis Media / Pain1
3CompletedTreatmentDrug Reaction to Analgesic Nos1
3CompletedTreatmentPharyngitis1
3CompletedTreatmentThroat Pain1
3TerminatedTreatmentAcute Otitis Media1
4CompletedPreventionAnesthesia of Mucous Membrane1
4CompletedPreventionNeonatal Infections1
4CompletedTreatmentAnalgesia / Pain Relief1
4CompletedTreatmentToothache1
4RecruitingTreatmentRadial Artery Spasm1
4Unknown StatusTreatmentDental Pain / Postoperative pain1
Not AvailableActive Not RecruitingTreatmentSpondyloarthritis1
Not AvailableCompletedBasic ScienceDepression1
Not AvailableCompletedTreatmentAge-Related Macular Degeneration (ARMD) / Central Retinal Vein Occlusion (CRVO) / Diabetic Macular Edema (DME)1
Not AvailableCompletedTreatmentAging / Pain1
Not AvailableCompletedTreatmentLocal Anesthesia / Postoperative pain / Self-Perception1
Not AvailableNot Yet RecruitingBasic ScienceChronic Low Back Pain (CLBP)1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingTreatmentAnaesthesia therapy / Surgery--Complications1
Not AvailableUnknown StatusTreatmentPain1
Not AvailableWithdrawnTreatmentPain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Alba Pharmacal
  • American Dental Cooperative Inc.
  • AR Medicom Inc.
  • Assured Packaging Inc.
  • Ballay Pharmaceuticals
  • Bausch & Lomb Inc.
  • Belport Co. Inc.
  • Benco Dental Co.
  • Beutlich Pharmaceuticals LP
  • Bio Pharm Inc.
  • Boca Pharmacal
  • Burkhart Dental Supply Inc.
  • Cao Group Inc.
  • Combe Inc.
  • County Line Pharmaceuticals LLC
  • Cross Country Paper Products Corp.
  • Crosstex International
  • Deepak Products Inc.
  • Dental Resources Inc.
  • Dental Technologies Inc.
  • DENTSPLY International
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DSHealthcare Inc.
  • Essence Dental LLC
  • Foremost Dental LLC
  • Germiphene Corp.
  • Great Southern Laboratories
  • Henry Schein Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Irisys Inc.
  • Laboratorios Zeyco SA De CV
  • Major Pharmaceuticals
  • Mallinckrodt Inc.
  • Marlop Pharmaceuticals Inc.
  • Medical Products Laboratories Inc.
  • Medtech Labs
  • Palmetto Pharmaceuticals Inc.
  • Patterson Dental Supply Inc.
  • Perrigo Co.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • PruGen Inc. Pharmaceuticals
  • Puretek Corp.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • River's Edge Pharmaceuticals
  • Sciarra Laboratories Inc.
  • SDA Laboratories Inc.
  • Sonar Products Inc.
  • Sunstar Pharmaceutical Inc.
  • Taro Pharmaceuticals USA
  • Taylor Pharmaceuticals
  • Trigen Laboratories Inc.
  • UCB Pharma
  • Vintage Pharmaceuticals Inc.
  • Wyeth Pharmaceuticals
Dosage forms
FormRouteStrength
StripDental10 mg/1
KitOral; Topical
KitTopical
KitOral; Topical
StickTopical100 mg/mL
CreamTopical7.5 g/100g
Aerosol, sprayTopical11.4 g/57g
OintmentTopical5.6 g/28g
StickTopical20 %
GelOral7.5 %
GelTopical20 %
GelOral
GelTopical100 mg/g
LiquidBuccal
SolutionTopical200 mg/mL
SolutionTopical100 mg/mL
GelOral.2 g/100g
LiquidTopical.2 mg/2mL
SolutionAuricular (otic)
LiquidTopical20 g/100mL
GelOral10 g/100g
Solution / dropsAuricular (otic)
GelTopical10 g/100g
LozengeOral15 mg/1
GelTopical210 mg/g
SprayTopical11.8 g/59mL
SprayTopical20 mL/100mL
GelDental230 mg/mL
GelTopical200 mg/mL
SwabTopical.12 mL/1
SwabTopical60 mg/mL
CreamTopical.2 g/g
LiquidTopical5 g/100g
CreamTopical5 g/100g
SprayTopical5 g/100g
CreamTopical5 g/100mL
OintmentTopical
OintmentTopical20 %
CreamTopical71.9395789 mg/mL
CreamTopical73.9395789 mg/mL
CreamTopical4.25 g/85.05g
GelOral9 mg/mL
GelTopical.2 g/g
LotionTopical
LiquidOral20 g/100mL
CreamTopical10 g/100g
SprayOral
Tablet, orally disintegratingOral6 mg/1
LozengeOral3 mg/1
LozengeOral4 mg/1
SwabTopical.06 mL/mL
AerosolTopical
OintmentTopical10 g/100g
GelTopical.075 g/g
SpongeTopical
Paste, dentifriceTopical200 mg/g
PasteDental
GelOral75 mg/g
LotionTopical50 mg/mL
OintmentTopical20 g/100g
Gel, dentifriceDental20 g/100g
Gel, dentifriceDental10 g/100g
Gel, dentifriceDental
LiquidDental; Topical200 mg/mL
GelDental
OintmentDental.2 g/mL
GelBuccal; Topical
OintmentTopical1.27 g/100g
LotionTopical.05 g/g
GelTopical7.5 %
GelTopical2410 mg/50mL
GelTopical50 mg/mL
SprayBuccal; Oral20 %
Aerosol, meteredTopical
LiquidRectal
LiquidTopical1417 mg/30mL
LiquidOral
LiquidOral7.5 mg/100mg
SprayOral7.5 mg/100mL
SprayTopical
PatchTopical6 g/100g
PatchTopical
GelDental6 g/30g
Spray, meteredDental11.4 g/57g
GelDental20 %
GelDental; Oral; Periodontal200 mg/1
LiquidDental20 %
LiquidDental; Oral; Periodontal200 mg/1
Aerosol, sprayTopical
Kit
CreamTopical
GelDental200 mg/g
SolutionOral
SuppositoryRectal
CreamTopical4.5 g/100g
SprayDental; Periodontal183 mg/g
LiquidTopical20 %
GelDental; Periodontal200 mg/g
SprayDental; Oral; Periodontal200 mg/g
GelDental; Oral; Periodontal200 mg/g
LiquidDental; Oral; Periodontal200 mg/g
AerosolDental; Topical21.9 %
SolutionTopical150 mg/mL
GelDental; Oral6.4 g/100g
LiquidTopical6 g/100g
LiquidDental
CreamTopical5 %
LiquidBuccal; Topical
LiquidBuccal200 mg/mL
CreamDental
GelTopical7 g/100mL
LozengeBuccal
GelOral20 g/100g
GranuleOral6 mg/1
LiquidTopical50 mg/mL
LiquidOral200 mg/mL
GelTopical3 g/100mL
GelTopical2.13 g/28.35g
SwabTopical.12 g/g
SwabTopical.12 g/.6mL
ClothTopical
SprayTopical11.4 g/57g
LiquidOral200 mg/g
GelTopical7.5 g/100g
LiquidTopical2.1 mg/30mL
CreamTopical200 mg/mL
Powder, for solutionOral90 mg/1
GelDental; Topical
GelBuccal
GelDental; Oral6.4 g/32g
Spray, meteredDental; Oral; Topical12 g/60g
Paste, dentifriceDental19.8 mg/g
LiquidDental205 mg
GelDental200 mg
LiquidTopical
SwabTopical.2 mL/mL
GelTopical200 mg/g
LiquidTopical200 mg/g
GelTopical
SwabTopical.075 mL/mL
GelTopical75 mg/g
Kit
LiquidTopical.2 mL/mL
Film, solubleOral
PasteTopical
GelOral.2 mL/mL
GelTopical20 g/100g
GelOral200 mg/g
OintmentTopical5 mg/g
SolutionTopical
LiquidTopical.009 mg/mL
LiquidTopical18.6 g/100mL
CreamTopical20 mg/100mg
SwabTopical
GelOral; Topical
Solution / dropsAuricular (otic)200 mg/mL
TabletOral
GelTopical5 g/100mL
LiquidTopical4 g/100mL
GelDental221 mg/g
GelDental; Topical20 %
GelTopical20 1/100g
CreamTopical4.2 g/56g
OintmentRectal
OintmentTopical200 mg/g
LiquidTopical200 mg/mL
GelOral200 mg/mL
Gel, dentifriceOral
Gel, dentifriceOral20 g/100g
LiquidDental20 g/100g
SwabTopical15 %
Powder, for solutionOral150 mg/3000mg
ClothTopical.0543 g/1
KitTopical
Aerosol, sprayTopical1.125 g/15g
GelTopical5.06 g/67.5g
GelTopical5.07 g/67.5g
SyrupDental1.8 %
Gum, chewingOral
LozengeOral
GelTopical2833 mg/60mL
SwabTopical6 g/100mL
SwabTopical.06 mg/1
SwabOral20 %
LiquidOral1.3 mg/13mL
OintmentTopical3.5 g/100g
LiquidOral50 mg/mL
Spray, meteredPeriodontal220 mg/g
GelOral; Topical20 %
GelOral; Topical200 mg
Gel, dentifriceDental220 mg/g
GelDental220 mg/g
GelDental6.96 g/30mL
GelDental231 mg/mL
EnemaRectal
SprayTopical7.5 g/100mL
Gel, dentifriceOral7.5 g/100g
Paste, dentifriceTopical20 g/100g
LiquidOral20 g/100g
Spray, meteredTopical
AerosolOral
GelTopical10 %
SwabTopical20 %
GelTopical.1 g/g
GelDental20 g/100g
Prices
Unit descriptionCostUnit
Americaine Anesthetic 20% Gel 28 gm Tube22.99USD tube
Americaine 20% ear drops1.26USD ml
Oticaine 20% ear drops0.83USD ml
Americaine lubricant0.71USD g
Hurricaine 20% liquid swab0.6USD swab
Hurricaine 20% spray0.52USD ml
Anbesol baby 7.5% gel0.41USD g
Cepacol 6 mg fizzlers tablet0.39USD tablet
Benzocaine powder0.09USD g
Dermoplast pain relieving spry0.07USD ml
Dermoplast spray0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)92 °CPhysProp
boiling point (°C)310 °CPhysProp
water solubility1310 mg/L (at 30 °C)YALKOWSKY,SH & HE,Y (2003)
logP1.86HANSCH,C ET AL. (1995)
pKa2.51 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility2.85 mg/mLALOGPS
logP2.2ALOGPS
logP1.5ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)2.78ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area52.32 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity47.53 m3·mol-1ChemAxon
Polarizability17.46 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.9609
Caco-2 permeable+0.7814
P-glycoprotein substrateNon-substrate0.8329
P-glycoprotein inhibitor INon-inhibitor0.9589
P-glycoprotein inhibitor IINon-inhibitor0.9612
Renal organic cation transporterNon-inhibitor0.8818
CYP450 2C9 substrateNon-substrate0.8426
CYP450 2D6 substrateNon-substrate0.7934
CYP450 3A4 substrateNon-substrate0.7513
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.937
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7883
Ames testNon AMES toxic0.8825
CarcinogenicityCarcinogens 0.513
BiodegradationReady biodegradable0.7718
Rat acute toxicity1.7665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9721
hERG inhibition (predictor II)Non-inhibitor0.9668
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.74 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS)GC-MSsplash10-00dl-0980000000-9bd6d020be04ce49bd3e
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-4900000000-9341302295e361a20bfd
GC-MS Spectrum - EI-BGC-MSsplash10-0109-9400000000-8e31c925b871e0f0299e
GC-MS Spectrum - EI-BGC-MSsplash10-0109-9400000000-c755b4e5336a2867357e
GC-MS Spectrum - EI-BGC-MSsplash10-01b9-1900000000-a811093acfd0672fece6
GC-MS Spectrum - CI-BGC-MSsplash10-014i-0900000000-49302e8e4fd5158a36da
GC-MS Spectrum - EI-BGC-MSsplash10-00di-5900000000-dcd2847110af7c87bf18
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00dl-0980000000-9bd6d020be04ce49bd3e
Mass Spectrum (Electron Ionization)MSsplash10-00xr-6900000000-0594451f3b181ab3c883
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-00kr-0900000000-b54aebb77e7a69ada07c
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-014i-5900000000-ce90658bd0fc66df820d
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-03xu-9100000000-5179b7804d2c59e71aa4
MS/MS Spectrum - EI-B (HITACHI RMU-7M) , PositiveLC-MS/MSsplash10-00di-4900000000-9341302295e361a20bfd
MS/MS Spectrum - EI-B (HITACHI RMU-7) , PositiveLC-MS/MSsplash10-0109-9400000000-8e31c925b871e0f0299e
MS/MS Spectrum - EI-B (HITACHI RMU-6D) , PositiveLC-MS/MSsplash10-0109-9400000000-c755b4e5336a2867357e
MS/MS Spectrum - EI-B (HITACHI M-60) , PositiveLC-MS/MSsplash10-01b9-1900000000-57d39b512bc5bdbb4987
MS/MS Spectrum - CI-B (HITACHI M-60) , PositiveLC-MS/MSsplash10-014i-0900000000-49302e8e4fd5158a36da
MS/MS Spectrum - EI-B (JEOL JMS-DX-300) , PositiveLC-MS/MSsplash10-00di-5900000000-dcd2847110af7c87bf18
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-014i-0900000000-a0f10abbe67842c2c958
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-00du-5900000000-43a89461a4d9cc5d1409
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-00dl-9600000000-049e2653cbbf24aaf010
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-002f-9100000000-6fbc7720b326773643af
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-00ou-9000000000-d7f7622c3a270c5ffcbb
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-e061a0f4172b47a8bd22
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00du-5900000000-54757e57c91d3eaa1976
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dl-9600000000-049e2653cbbf24aaf010
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-002f-9100000000-e16fc2db7a632fc6f4da
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00ou-9000000000-d7f7622c3a270c5ffcbb
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-5900100000-72ac4bcb64db0d25261e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-2900000000-89639c79865df34d7081
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-2900000000-2132ea2de3c0db3e47fa
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
Aminobenzoic acids and derivatives / Benzoyl derivatives / Aniline and substituted anilines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Primary amines / Organopnictogen compounds / Organooxygen compounds / Organic oxides
show 1 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / Benzoyl / Aniline or substituted anilines / Amino acid or derivatives / Carboxylic acid ester / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Amine / Organonitrogen compound
show 8 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
substituted aniline, benzoate ester (CHEBI:116735)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Ahern CA, Eastwood AL, Dougherty DA, Horn R: Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94. Epub 2007 Oct 25. [PubMed:17967784]
  4. Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM, Sheets MF: Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res. 2009 Aug 28;105(5):492-9. doi: 10.1161/CIRCRESAHA.109.198572. Epub 2009 Aug 6. [PubMed:19661462]
  5. Lipkind GM, Fozzard HA: Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol. 2005 Dec;68(6):1611-22. Epub 2005 Sep 20. [PubMed:16174788]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Bell FP: The effect of local anesthetics on arterial lipid metabolism. Inhibition of sterol esterification in vitro. Atherosclerosis. 1981 Jan-Feb;38(1-2):81-8. [PubMed:7470208]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]

Drug created on June 13, 2005 07:24 / Updated on July 19, 2018 17:49